| 产品描述: | Faropenem sodium是具有口服活性的β-内酰胺抗生素,用于研究治疗肺结核和社区获得性肺炎的试验中。 |
| 靶点: |
Antibacterial;Antibiotic |
| 体内研究: |
Faropenem (500 mg/kg,口服,感染后第 1 至 7 天) sodium 可降低小鼠急性结核病感染模型中的细菌 (结核分枝杆菌) 负荷。 Faropenem (10-80 mg/kg/天,腹腔注射,感染后 24 h,间隔 4、6 和 12 h,共 14 天) sodium在小鼠暴露后预防吸入模型中表现出对抗炭疽杆菌的高水平活性。 |
| 细胞实验: |
Cell lines: RAW macrophages Concentrations: 7, 28, or 56 μg/ml Incubation Time: -- Method: RAW macrophages were grown in Dulbecco modified Eagle medium containing l-glutamine and sodium pyruvate (PAA Laboratories) supplemented with 10% fetal bovine serum. About 2.5 × 104 cells were seeded into each well of a 48-well plate and were infected with green fluorescent protein (GFP)-expressing M. tuberculosis (MTB_NDT1) at a multiplicity of infection (MOI) of 10:1 for 4 h. After infection, the monolayers were washed three times with fresh medium to remove nonadherent bacteria and then exposed to fresh medium with or without isoniazid (0.75 μg/ml), faropenem (7, 28, or 56 μg/ml), or meropenem (5, 25, or 50 μg/ml) plus clavulanate (2.5 μg/ml). Medium (containing antibiotics) was changed every 24 h. At various time points, macrophages were washed once with 1× PBS and then lysed using 0.5% Triton X-100. The macrophage lysates were diluted in PBS containing 0.05% Tween 80, serial dilutions were plated on 7H10 agar, a |
| 动物实验: |
Animal Models: Adult female C57BL/6J mice Dosages: 500 mg/kg Administration: oral |
| 参考文献: |
1. Dhar N, et al. Antimicrob Agents Chemother. 2015, 59(2):1308-19. |
| 溶解性: |
Soluble in DMSO、H2O |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.254 ml |
16.271 ml |
32.542 ml |
| 5 mM |
0.651 ml |
3.254 ml |
6.508 ml |
| 10 mM |
0.325 ml |
1.627 ml |
3.254 ml |
| 50 mM |
0.065 ml |
0.325 ml |
0.651 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |